Almirall, S.A. (ALM) and WuXi Biologics have signed an agreement to develop innovative biologics for dermatology diseases including atopic dermatitis. Under the agreement, Almirall has access to WuXi Biologics’ antibody platforms including WuXiBody to discover multiple novel bispecific antibodies. This strategic collaboration allows Almirall to develop the medication under license and maintain ownership of the resulting compounds. Bhushan Hardas, MD, MBA, chief scientific officer o...